Socio-economic aspects of neuroimmunological diseases (Journal of Neurology (2006) 253, (SUPPL. 5) (87-90) DOI: 10.1007/s00415-006-5015-x);Socio-economic aspects of neuroimmunological diseases

Journal of Neurology

Volumn 253, Issue SUPPL. 5, 2006, Pages 308-

  Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cost effectiveness; Economic models; Immunomodulatory treatment; QALY

Indexed keywords

IMMUNOGLOBULIN; PREDNISOLONE; PREDNISONE; RECOMBINANT BETA INTERFERON;

CHRONIC DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DRUG COST; DRUG DOSE REDUCTION; HUMAN; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROLOGIC DISEASE; OCCUPATIONAL HEALTH; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT COURSE THERAPY; WORK CAPACITY;

EID: 33748970441     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0881-z     Document Type: Erratum

References (21)

1. Chilcott J et al. (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 326(7388):522; discussion 522
2. Fauci AS, Wolff SM, Johnson JS (1971) Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 285(27):1493-1496
3. Flachenecker P, Rieckmann P (2004) Health outcomes in multiple sclerosis. Curr Opin Neurol 17(3):257-261
4. Freedman MS et al. (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31(2):157-168
5. Goodin D et al. (2002) Disease modifying therapies in multiple sclerosis - Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
6. Heller JG (2002) Will public health survive QALYs? Can J Clin Pharmacol 9(1):5-6
7. Henriksson F et al. (2001) Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 8(1):27-35
8. Hohlfeld R et al. (1998) Azathioprine toxicity during long term immmunosuppression of generalized myasthenia gravis. Neurology 38:258-261
9. Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Brain 120:865-916
10. International Working Group for Treatment Optimization in MS (2004) Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 11(1):43-47
11. Kobelt G (2004) Economic evidence in multiple sclerosis: a review. Eur J Health Econ 5(Suppl 1):S54-S62
12. Kobelt G et al. (2001) Costs and Quality of Life in Multiple Sclerosis. An observational study in Germany. Health Economics in Prevention and Care 2:60-68
13. Mertens HG, Balzereit F, Leipert M (1969) The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 2(6):321-339
14. Miller D, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23
15. McCrone P et al. (2003) Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10(6):687-694
16. Nagpal S et al. (1999) Treatment of Guillain-Barré Syndrome: a cost-effectiveness analysis. J Clin Apheresis 14:107-113
17. Plasma Exchange/Sandoglobulin GBS Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. The Lancet 349:225-230
18. Rieckmann P et al. (2004) Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 251(11):1329-1339
19. Sheridan C, Katsnelson A (2005) Cost-effectiveness data on biologics needed. Nat Biotechnol 23(3):272-273
20. van der Meché F, Schmitz, and DG, Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 326:1123-1129
21. Williams JP, Meyers JA (2002) Immune-mediated inflammatory disorders (I. M. I. D.s): the economic and clinical costs. Am J Manag Care 8(21 Suppl):S664-S681; quiz S682-S685